The general anesthetic propofol has been shown to be cardioprotective. However, its benefits when used in cardioplegia during cardiac surgery have not been demonstrated. In this study, we investigated the effects of propofol on metabolic stress, cardiac function, and injury in a clinically relevant model of normothermic cardioplegic arrest and cardiopulmonary bypass. Twenty anesthetized pigs, randomized to propofol treatment (n = 8) and control (n =12) groups, were surgically prepared for cardiopulmonary bypass (CPB) and cardioplegic arrest. Doses of warm blood cardioplegia were delivered at 15-min intervals during a 60-min aortic cross-clamped period. Propofol was continuously infused for the duration of CPB and was therefore present in blood cardioplegia. Myocardial biopsies were collected before, at the end of cardioplegic arrest, and 20 mins after the release of the aortic cross-clamp. Hemodynamic parameters were monitored and blood samples collected for cardiac troponin I measurements. Propofol infusion during CPB and before ischemia did not alter cardiac function or myocardial metabolism. Propofol treatment attenuated the changes in myocardial tissue levels of adenine nucleotides, lactate, and amino acids during ischemia and reduced cardiac troponin I release on reperfusion. Propofol treatment reduced measurable hemodynamic dysfunction after cardioplegic arrest when compared to untreated controls. In conclusion, propofol protects the heart from ischemia-reperfusion injury in a clinically relevant experimental model. Propofol may therefore be a useful adjunct to cardioplegic solutions as well as being an appropriate anesthetic for cardiac surgery.
Get full access to this article
View all access options for this article.
References
1.
Bryson HM, Fulton BR, Faulds D. Propofol: an update of its use in anesthesia and conscious sedation. Drugs50:513–559, 1995.
2.
Kato R, Foex P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. Can J Anaesth49:777–791, 2002.
3.
Kokita N, Hara A, Abiko Y, Arakawa J, Hashizume H, Namiki A. Propofol improves functional and metabolic recovery in ischemic reperfused isolated rat hearts. Anesth Analg86:252–258, 1998.
4.
Kokita N, Hara A. Propofol attenuates hydrogen-peroxide induced mechanical and metabolic derangements in the isolated rat heart. Anesthesiology84:117–127, 1996.
5.
Ko SH, Yu CW, Lee SK, Choe H, Chung MJ, Kwak YG, Chae SW, Song HS. Propofol attenuates ischaemic-reperfusion injury in the isolated rat heart. Anesth Analg85:719–724, 1997.
6.
Xia ZY, Godin DV, Chang TKH, Ansley DM. Dose-dependent protection of cardiac function by propofol during ischemia and early reperfusion in rats: effects on 15-F-2t-isoprostane formation. Can J Physiol Pharmacol81:14–21, 2003.
7.
Stratford N, Murphy P. Antioxidant activity of propofol in blood from anaesthetized patients. Eur J Anaesthesiol15:158–160, 1998.
8.
Buljubasic N, Marijic J, Berczi V, Supan DF, Kampine JP, Bosnjak ZJ. Differential effects of etomidate, propofol, and midazolam on calcium and potassium channel currents in canine myocardial cells. Anesthesiology85:1092–1099, 1996.
9.
Li YC, Ridefelt P, Wiklund L, Bjerneroth G. Propofol induces a lowering of free cytosolic calcium in myocardial cells. Acta Anaesth Scand41:633–638, 1997.
10.
Reimer KA, Jennings RB. Myocardial ischemia, hypoxia and infarction. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, Eds. The Heart and Cardiovascular System. New York: Raven Press, pp1875–1973, 1992.
11.
Lemasters JJ, Thurman RG. The many facets of reperfusion injury. Gastroenterology108:1317–1320, 1995.
12.
Halestrap AP. Interactions between oxidative stress and calcium overload on mitochondrial function. In: Darley-Usmar V, Schapira AHV, Eds. Mitochondria: DNA, Proteins and Disease. London: Portland Press, pp113–142, 1994.
13.
Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection. Cardiovasc Res61:372–385, 2004.
14.
Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J307:93–98, 1995.
15.
Griffiths EJ, Halestrap AP. Protection by cyclosporin a of ischemia reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol25:1461–1469, 1993.
16.
Halestrap AP, Connern CP, Griffiths EJ, Kerr PM. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol Cell Biochem174:167–172, 1997.
17.
Kerr PM, Suleiman MS, Halestrap AP. Recovery of rat hearts reperfused after a period of ischemia is accompanied by reversal of the mitochondrial permeability transition and is enhanced by pyruvate. Am J Physiol276:H496–H502, 1999.
18.
Suleiman MS, Halestrap AP, Griffiths EJ. Mitochondria: a target for myocardial protection. Pharmacol Ther89:29–46, 2001.
19.
Javadov SA, Lim KHH, Kerr PM, Suleiman MS, Angelini GD, Halestrap AP. Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc Res45:360–369, 2000.
20.
Thompson K, Wisenberg G, Sykes J, Thompson RT. Similar long-term cardiovascular effects of propofol or isoflurane anesthesia during ischemia/reperfusion in dogs. Can J Anaesth49:978–985, 2002.
21.
Coetzee A. Comparison of the effects of propofol and halothane on acute myocardial ischaemia and myocardial reperfusion injury. South Afr Med J86:C85–C90, 1996.
22.
De Hert SG, ten Broecke PW, Mertens E, Van Sommeren EW, De Blier IG, Stockman BA, Rodrigus IE. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology97:42–49, 2002.
23.
Sayin MM, Ozatamer O, Tasoz R, Kilinc K, Unal N. Propofol attenuates myocardial lipid peroxidation during coronary artery bypass grafting surgery. Br J Anaesth89:242–246, 2002.
24.
Xia Z, Luo T. Sevoflurane or desflurane anesthesia plus postoperative propofol sedation attenuates myocardial injury after coronary surgery in elderly high-risk patients. Anesthesiology100:1038–1039, 2004.
25.
De Hert SG, Van der Linden PJ. Anesthesiology100:1039–1040, 2004.
26.
Lim KHH, Modi P, Nicholson E, Lawrance L, Halestrap AP, Angelini GD, Suleiman MS. A pig model of warm-blood cardioplegic arrest to investigate the cardioprotective effects of propofol (abstract). J Physiol536P, 2001.
Yoshitani K, Kawaguchi M, Takahashi M, Kitaguchi K, Furuya H. Plasma propofol concentration and EEG burst suppression ratio during normothermic cardiopulmonary bypass. Br J Anaesth90:122–126, 2003.
29.
Hiraoka H, Yamamoto K, Okano N, Morita T, Goto F, Horiuchi R. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Ther75:324–330, 2004.
30.
Rosen DA, Rosen KR. Elimination of drugs and toxins during cardiopulmonary bypass. J Cardiothorac Vasc Anesth11:337–340, 1997.
31.
Imura H, Ayres BE, Suleiman M-S. Purine metabolism and release during cardioprotection with hyperkalaemia and hypothermia. Mol Cell Biochem237:119–127, 2002.
32.
Imura H, Caputo M, Parry A, Pawade A, Angelini GD, Suleiman MS. Age-dependent and hypoxia-related differences in myocardial protection during pediatric open heart surgery. Circulation103:1551–1556, 2001.
33.
Servin F, Desmonts JM, Haberer JP, Cockshott ID, Plummer GF, Farinotti R. Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology69:887–891, 1988.
34.
Cockshott ID. Propofol (“Diprivan”) pharmacokinetics and metabolism—an overview. Postgrad Med J61:45–50, 1985.
35.
Sztark F, Ichas F, Ouhabi R, Dabadie P, Mazat JP. Effects of the anaesthetic propofol on the calcium-induced permeability transition of rat heart mitochondria: direct pore inhibition and shift of the gating potential. FEBS Lett368:101–104, 1995.
36.
Branca D, Vincenti E, Scutari G. Influence of the anesthetic 2,6-diisopropylphenol (propofol) on isolated rat heart mitochondria. Comp Biochem Physiol C: Pharmacol Toxicol Endocrinol110:41–45, 1995.
37.
Rigoulet M, Devin A, Averet N, Vandais B, Guerin B. Mechanisms of inhibition and uncoupling of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol. Eur J Biochem241:280–285, 1996.
38.
Mayer N, Legat K, Weinstabl C, Zimpfer M. Effects of propofol on the function of normal, collateral-dependent, and ischemic myocardium. Anesth Analg76:33–39, 1993.
39.
Schenkman KA, Yan SL. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med28:172–177, 2000.
40.
Leather HA, De Wolff MH, Wouters PE. Effects of propofol on the systolic and diastolic performance of the postischaemic, reperfused myocardium in rabbits. Eur J Anaesthesiol20:191–198, 2003.
41.
Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KHH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol Lond549:513–524, 2003.
42.
DiLisa F, Menabo R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD(+) and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem276:2571–2575, 2001.
43.
Borutaite V, Budriunaite A, Morkuniene R, Brown GC. Release of mitochondrial cytochrome c and activation of cytosolic caspases induced by myocardial ischaemia. Biochim Biophys Acta537:101–109, 2001.
44.
Borutaite V, Jekabsone, A, Morkuniene R, Brown GC. Inhibition of mitochondrial permeability transition prevents mitochondrial dysfunction, cytochrome c release and apoptosis induced by heart ischemia. J Mol Cell Cardiol35:357–366, 2003.
45.
Suleiman MS. New concepts in the cardioprotective action of magnesium and taurine during the calcium paradox and ischaemia of the heart. Magnes Res7:295–312, 1994.
46.
Sprung J, Ogletree-Hughes ML, McConnell BK, Zakhary DR, Smolsky SM, Moravec CS. The effects of propofol on the contractility of failing and nonfailing human heart muscles. Anesth Analg93:550–559, 2001.
47.
Kawano T, Oshita S, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Takahashi A, Nakaya Y. Clinically relevant concentrations of propofol have no effect on adenosine triphosphate-sensitive potassium channels in rat ventricular myocytes. Anesthesiology96:1472–1477, 2002.
48.
Klockgether-Radke AP, Schulze H, Neumann P, Hellige G. Activation of the K+ channel BKCa is involved in the relaxing effect of propofol on coronary arteries. Eur J Anaesthesiol21:226–230, 2004.
49.
Ko S-H, Yu C-W, Lee S-K, Choe H, Chung M-J, Kwak Y-G, Chae S-W, Song H-S. Propofol attenuates ischemia-reperfusion injury in the isolated rat heart. Anesth Analg85:719–724, 1997.
50.
Leather HA, De Wolff MH, Wouters PE. Effects of propofol on the systolic and diastolic performance of the postischaemic, reperfused myocardium in rabbits. Eur J Anaesthesiol20:191–198, 2003.
51.
De la Cruz JP, Zanca A, Carmona JA, de la Cuesta FS. The effect of propofol on oxidative stress in platelets from surgical patients. Anesth Analg89:1050–1055, 1999.
